193.9300 6.93 (3.71%)
NSE Nov 11, 2025 15:31 PM
Volume: 2.2M
 

193.93
3.71%
Karvy
The company reported revenue growth of 8.9% for Q4FY15 over Q4FY14 and annual revenue reported a growth of 26.4% for FY15 over FY14.The company's Europe & UK segment reported growth of 25.7% while the US & North America reported growth of 65.3%. The improved product mix is reflected in operating margins which to 23.2% from 19.2% in FY14
Marksans Pharma Ltd. is trading below its 100 day SMA of 202.3
More from Marksans Pharma Ltd.
Recommended